Form 4: Relmada Therapeutics Director Fabiana Fedeli Acquires Stock Options

Director Fabiana Fedeli acquired stock options in Relmada Therapeutics, Inc. on June 26, 2025.

Summary

• Fabiana Fedeli, a director of Relmada Therapeutics, Inc., acquired stock options to purchase 100,000 shares of common stock on June 26, 2025.
• The exercise price of the stock options is $0.67 per share.
• The options vest in 16 equal quarterly installments commencing on September 26, 2025.
• The expiration date of the options is June 26, 2035.
• Following the transaction, Fedeli directly owns 100,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The acquisition of stock options by a director is generally viewed as a positive sign, indicating confidence in the company's future.

Positives

• A director increasing their holdings in the company may signal confidence in the company's future prospects.

Future Outlook

The stock options vest in 16 equal quarterly installments commencing on September 26, 2025, suggesting a long-term alignment of interest between the director and the company's performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• Shareholders: Insider transactions are often monitored by shareholders as indicators of management's confidence in the company.
• Employees: The vesting schedule of the options may align the director's interests with the long-term success of the company, potentially benefiting employees.

Key Dates

Recommendation

Keywords

stock options, Form 4, beneficial ownership, director, Relmada Therapeutics, RLMD, equity securities